1 Number That Should Shock Fulgent Genetics Investors
Shareholders of Fulgent Genetics (NASDAQ: FLGT) have been on quite a ride over the past year. The diagnostics company has subjected investors to both euphoria and despair. COVID-19 ushered in an era of testing that propelled shares to huge gains, and the authorization of vaccines convinced Wall Street the boom was behind us.
The numbers looking back have been amazing, but there's one estimate that should give shareholders a lot of optimism about the company's future.
Image source: Getty Images.
Source Fool.com
